As the introduction of artificial intelligence (AI)-powered diagnostic tools indicates the medical industry’s shift towards precision medicine approaches, a new report on Monday said that these tools enable a more personalised technique to healthcare by analysing biological and clinical data using advanced algorithms that account for individual patient characteristics, biomarkers, and disease profiles.
According to the leading data and analytics company GlobalData, precision medicine presents a larger trend of tailoring therapeutic interventions to improve treatment efficacy and safety.
“Integrating AI-powered digital health solutions into the existing healthcare systems, such as electronic medical records (EMRs), gives clinicians easy access to diagnostic insights and patient data,” said Elia Garcia, Medical Analyst at GlobalData.
“The AI/machine learning (ML) software, which is directly integrated into hospital EMRs, boosts clinical workflow efficiency, collaborative decision-making and patient safety,” she added.
As per the analysts, AI is rapidly being adopted in the medical field, with many medical devices starting to incorporate AI capabilities. These AI capabilities include — advanced imaging systems, smart robots, wearable technology, AI-based data analysis, simulation platforms, and others.
The software as a medical device (SaMD) categorises patients into risk groups based on their sepsis risk score, providing clinicians with useful information about the likelihood of deterioration, hospital length of stay, and the need for escalated care, the report noted.
Identifying high-risk patients early allows healthcare providers to allocate resources more efficiently and tailor interventions, leading to fewer adverse outcomes, it added.
“To summarise, AI has enormous potential to improve patient safety in healthcare facilities by enabling early detection and diagnosis, risk assessment and prediction, seamless integration with existing healthcare systems, and the development of personalised therapeutic interventions,” Garcia said.
She further mentioned that the US Food and Drug Administration’s (FDA) approval of the first AI diagnostic tools for sepsis is a significant step forward in realising “AI’s potential to improve patient care and outcomes in acute care settings”.